These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9241714)

  • 1. Optimizing the treatment of the dialysis patient: a painful lesson.
    Depner TA
    Semin Nephrol; 1997 Jul; 17(4):285-97. PubMed ID: 9241714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Renal replacement therapy by hemodialysis: an overview].
    Jacobs C
    Nephrol Ther; 2009 Jul; 5(4):306-12. PubMed ID: 19481513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should dialysis modalities be designed to remove specific uremic toxins?
    Baurmeister U; Vienken J; Ward RA
    Semin Dial; 2009; 22(4):454-7. PubMed ID: 19709001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Problems and solutions for artificial kidney.
    Vanholder R
    Technol Health Care; 2000; 8(6):373-9. PubMed ID: 11258583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urea kinetic modelling in two groups of patients on continuous ambulatory peritoneal dialysis.
    Barton EN; Morgan AG; Burden RP
    West Indian Med J; 1997 Jun; 46(2):57-9. PubMed ID: 9260536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uremic toxins: a new focus on an old subject.
    Yavuz A; Tetta C; Ersoy FF; D'intini V; Ratanarat R; De Cal M; Bonello M; Bordoni V; Salvatori G; Andrikos E; Yakupoglu G; Levin NW; Ronco C
    Semin Dial; 2005; 18(3):203-11. PubMed ID: 15934967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of the number of peritonitis episodes on peritoneal membrane function].
    Jovanović D; Nesić V; Dimitrijević Z
    Srp Arh Celok Lek; 1999; 127(1-2):28-31. PubMed ID: 10377837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uraemic itching: do polymethylmethacrylate dialysis membranes play a role?
    Aucella F; Vigilante M; Gesuete A; Maruccio G; Specchio A; Gesualdo L
    Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v8-12. PubMed ID: 17586845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of furosemide in patients on peritoneal dialysis.
    Flinn A; Ledger S; Blake P
    CANNT J; 2006; 16(3):40-4. PubMed ID: 17061696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dialyzer membrane permeability and survival in hemodialysis patients.
    Chauveau P; Nguyen H; Combe C; Chêne G; Azar R; Cano N; Canaud B; Fouque D; Laville M; Leverve X; Roth H; Aparicio M;
    Am J Kidney Dis; 2005 Mar; 45(3):565-71. PubMed ID: 15754279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease severity adversely affects delivery of dialysis in acute renal failure.
    Schiffl H
    Nephron Clin Pract; 2007; 107(4):c163-9. PubMed ID: 17975323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment time, chronic inflammation, and hemodynamic stability: the overlooked parameters in hemodialysis quantification.
    Zsom L; Zsom M; Fulop T; Flessner MF
    Semin Dial; 2008; 21(5):395-400. PubMed ID: 18945325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein in the diets of dialyzed and non-dialyzed uremic patients. Study with nitrogen-labeled urea.
    Smith EB; Hill PA
    J Am Diet Assoc; 1972 May; 60(5):389-93. PubMed ID: 5018368
    [No Abstract]   [Full Text] [Related]  

  • 15. Estimation of residual glomerular filtration rate and renal Kt/Vurea from creatinine clearance in end-stage renal disease patients. The Netherlands Cooperative Study on the Adequacy of Dialysis.
    Korevaar JC; Jansen MA; Dekker FW; Boeschoten EW; Krediet RT
    Adv Perit Dial; 1999; 15():132-7. PubMed ID: 10682088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dialysis dose and frequency.
    Locatelli F; Buoncristiani U; Canaud B; Köhler H; Petitclerc T; Zucchelli P
    Nephrol Dial Transplant; 2005 Feb; 20(2):285-96. PubMed ID: 15598667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of small solute clearance in hemodialysis.
    Huang Z; Clark WR; Gao D
    Semin Dial; 2005; 18(1):30-5. PubMed ID: 15663761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dramatic reduction of normalized protein catabolic rate occurs late in the course of progressive renal insufficiency.
    Chandna SM; Kulinskaya E; Farrington K
    Nephrol Dial Transplant; 2005 Oct; 20(10):2130-8. PubMed ID: 15956057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment frequency and duration.
    Leypoldt JK
    Semin Dial; 2005; 18(5):401-8. PubMed ID: 16191181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose.
    Vilar E; Wellsted D; Chandna SM; Greenwood RN; Farrington K
    Nephrol Dial Transplant; 2009 Aug; 24(8):2502-10. PubMed ID: 19240122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.